OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of intravenous (IV) secukinumab in patients with active psoriatic arthritis (PsA). METHODS: INVIGORATE-2 (NCT04209205) was a randomized, placebo-controlled, phase 3 trial. Patients with active PsA were randomized 1:1 to receive IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks [q4w]) or placebo. At week 16, patients randomized to placebo were switched to IV secukinumab (3 mg/kg q4w), and patients who received IV secukinumab continued treatment through week 52. The primary efficacy endpoint was achievement of 50% improvement in American College of Rheumatology response criteria (ACR50) at week 16. Efficacy and safety were evaluated through weeks 52 and 60, respectively. RESULTS: Among 191 patients randomized to IV secukinumab and 190 to placebo/IV secukinumab, 177 (92.7%) and 170 (89.5%) completed the entire study period, respectively. A significantly higher proportion of patients who received IV secukinumab versus placebo achieved ACR50 at week 16 (31.4% vs 6.3%; adjusted P < 0.0001). All secondary efficacy endpoints were met at week 16 (all adjusted P < 0.05 using the predefined hypothesis-testing hierarchy). Patients who switched from placebo to secukinumab at week 16 showed rapid improvements in ACR50 rates; by week 52, both treatment arms experienced similar improvements in efficacy outcomes. No new or unexpected safety signals were observed with receiving IV secukinumab. One death was reported in the placebo group before week 16. CONCLUSION: IV secukinumab led to rapid and sustained improvements in clinical measures of PsA, and the safety profile was consistent with that of secukinumab administered subcutaneously.

Altoona Center for Clinical Research Duncansville Pennsylvania

Arthritis Center of Nebraska Lincoln

Highlands Advanced Rheumatology and Arthritis Center Avon Park Florida

Institute of Rheumatology and Charles University Prague Prague Czech Republic

Integral Rheumatology and Immunology Specialists Plantation Florida

Novartis Ireland Ltd Dublin Ireland

Novartis Pharma AG Basel Switzerland

Novartis Pharmaceuticals Corporation East Hanover New Jersey

Sharp Community Medical Group La Mesa California

SouthWest Arthritis Research Group Mesquite Texas

See more in PubMed

Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res 2019;8:1665. PubMed PMC

Azuaga AB, Ramírez J, Cañete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci 2023;24:4901. PubMed PMC

Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol 2018;14:405–417. PubMed

Lee S, Xie L, Wang Y, et al. Comorbidity and economic burden among moderate‐to‐severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. J Med Econ 2018;21:564–570. PubMed

Kolbinger F, Di Padova F, Deodhar A, et al. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacol Ther 2022;229:107925. PubMed

Cosentyx® (Secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, October 2023.

European Medicines Agency . Cosentyx: Summary of Product Characteristics. Novartis Europharm Limited. Accessed August 16, 2023. https://www.ema.europa.eu/en/documents/product‐information/cosentyx‐epar‐product‐information_en.pdf

McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti‐interleukin‐17a monoclonal antibody, in patients with psoriatic arthritis (future 2): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet 2015;386:1137–1146. PubMed

Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo‐controlled trial (FUTURE 3). Arthritis Res Ther 2018;20:47. PubMed PMC

Kivitz AJ, Nash P, Tahir H, et al. Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol Ther 2019;6:393–407. PubMed PMC

Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double‐blind, phase III FUTURE 5 study. Ann Rheum Dis 2018;77:890–897. PubMed PMC

Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin‐17a in patients with psoriatic arthritis. N Engl J Med 2015;373:1329–1339. PubMed

Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford) 2020;59(Suppl 1):i37–i46. PubMed PMC

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–2673. doi:10.1002/art.21972 PubMed DOI

Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729–740. doi:10.1002/art.1780360601 PubMed DOI

American College of Rheumatology Committee to Reevaluate Improvement Criteria . A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57(2):193–202. doi:10.1002/art.22552. Erratum in: Arthritis Rheum. 2007 Dec 15;57(8):1574. PubMed DOI

Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69(1):48–53. PubMed

Bretz F, Maurer W, Brannath W, et al. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009;28(4):586–604. PubMed

Coates LC, Mease PJ, Gossec L, et al. Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study. Arthritis Care Res (Hoboken) 2018;70:1529–1535. PubMed

van der Heijde D, Mease PJ, Landewé RB, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52‐week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford) 2020;59:1325–1334. PubMed PMC

McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double‐blind, parallel‐group, randomised, active‐controlled, phase 3b trial. Lancet 2020;395:1496–1505. PubMed

Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo‐controlled trial (future 3). Arthritis Res Ther 2018;20:47. PubMed PMC

Aletaha D, Husni ME, Merola JF, et al. Treatment mode preferences in psoriatic arthritis: a qualitative multi‐country study. Patient Prefer Adherence 2020;14:949–961. PubMed PMC

Xu Y, Sudharshan L, Hsu MA, et al. Patient preferences associated with therapies for psoriatic arthritis: a conjoint analysis. Am Health Drug Benefits 2018;11:408–417. PubMed PMC

Ogdie A, Myers K, Mansfield C, et al. Experiences and treatment preferences in patients with psoriatic arthritis: a cross‐sectional study in the ArthritisPower registry. Rheumatol Ther 2022;9:735–751. PubMed PMC

Bolge SC, Eldridge HM, Lofland JH, et al. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Prefer Adherence 2017;11:661–669. PubMed PMC

Højgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor‐α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 2016;55:2191–2199. PubMed